Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project

Abstract Background Primary debulking surgery (PDS) is the main treatment for patients with advanced ovarian cancer, and neoadjuvant chemotherapy (NACT) is for bulky stage III-IV patients who are poor surgical candidates and/or for whom there is a low likelihood of optimal cytoreduction. NACT can increase the rate of complete cytoreduction, but this advantage has not translated to an improvement in survival. Therefore, we aimed to identify factors associated with the survival of patients who received NACT followed by interval debulking surgery (IDS). Methods A retrospective study was conducted in FIGO stage IIIC-IV epithelial ovarian cancer patients who underwent PDS or IDS in our center between January 1st, 2013, and December 31st, 2018. Results A total of 273 cases were included, of whom 20 were lost to follow-up. Progression-free survival (PFS) and overall survival (OS) of the IDS and PDS groups were found to be similar, although the proportion of patients in stage IV and serum carbohydrate antigen 125 (CA125) levels before treatment in the IDS group were significantly higher than that in the PDS group. Body mass index (BMI), CA125 level before IDS, residual disease after surgery, and the interval between preoperative and postoperative chemotherapy were all found to be independent prognostic factors for PFS; FIGO stage, residual disease after surgery, and CA125 level before IDS were independent prognostic factors for OS. We found that PFS and OS were both significantly longer in patients with normal CA125 levels before IDS and when the interval between preoperative and postoperative chemotherapy was < 35.5 days (IDS-3 group) than for patients in the PDS group. Conclusions The results suggested the importance of timely IDS and postoperative chemotherapy and potentially allowed the identification of patients who would benefit the most from NACT. Normal CA125 levels before IDS and an interval between preoperative and postoperative chemotherapy no longer than 5 weeks were associated with improved prognosis in advanced ovarian cancer patients.

Download Full-text

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

BMC Cancer ◽

10.1186/1471-2407-8-27 ◽

2008 ◽

Vol 8 (1) ◽

Cited By ~ 15

Author(s):

Jolanta Kupryjanczyk ◽

◽

Ewa Kraszewska ◽

Izabela Ziolkowska-Seta ◽

Radoslaw Madry ◽

...

Keyword(s):

Ovarian Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Tp53 Status

Download Full-text

Long Non-Coding RNA- PVT1 in Ovarian Cancer as Predictors for Platinum Analogues Resistance

QJM ◽

10.1093/qjmed/hcab103.002 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Walid Abd Almonem Biomy ◽

Mohamed Yassin Mostafa ◽

Nashwa Nagy EL-Khazragy ◽

Khaled Kamal Eldein Ghonem ◽

Amr Attia Hewety

Keyword(s):

Ovarian Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Complete Blood Count ◽

Ovarian Tissue ◽

Treatment Modalities ◽

Control Group ◽

Presenting Symptoms ◽

Significant Difference ◽

Normally Distributed

Abstract Background Ovarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. Objectives The aim of this retrospective study was to assess expression of the Lnc_PVT1 in the studied subjects. The expression of Lnc_PVT1 biomarker; was compared in ovarian cancer patients versus the non-cancerous tissue. The data normalization was tested by normality test which shows that the biomarker expression is not normally distributed; thus, a Mann Whitney statistics test for non -parametric values was applied. Our results showed a high significant difference in the expression of Lnc-PVT1 (p < 0.01). Lnc_PVT1 expression is upregulated by 2.4 folds in ovarian cancer patients (median: 32.0; range: 11 – 92) compared to control group (median: 13.0; range: 11 – 16). Methods and Materials This is a retrospective study. Include patients with advanced epithelial ovarian cancer (stage II and IV) who received chemotherapy platinum based and taxines from 2014-2017. Setting: Clinical oncology department Ain Shams University, Egypt, Demerdash hospital. Data collection: The following information will be ANONYMOUSLY extracted from the patient medical files: age at diagnosis, presenting symptoms, laboratory investigations: (Liver function, kidney function, complete blood count &tumor markers), tumor histological type, tumor FIGO stage& degree of differentiation, treatment modalities, type of surgery, chemotherapy regimens (Adjuvant, Neoadjuvant or palliative), chemotherapy responsiveness or resistance, disease recurrence and disease-free period, and patients' survival. Results The current study was enrolled on 55 subjects, they classified into two subgroups. The ovarian cancer cases constitute 45 patients; samples collected from patients after diagnosis has been confirmed by histopathology based on immune-histochemical analysis as well as Computerized axial tomography (CT scan) and Magnetic resonance imaging (MRI). The cancer ovary patients were compared to ten non- malignant ovarian tissues. Table 1 illustrates the demographic and clinical data of the studied subjects. We test the normality for age; the data was normally distributed. For this reason, we represent the data in mean value and standard deviation form. Matched age and gender was observed between ovarian cancer patients and healthy control. The mean age for the studied subjects was 47.7±9.1. In our study; the Cisplatin resistant patients (n = 25) had a mean age of 46±5 compared to Cisplatin sensitive which were older (mean: 50 ±11.5). Regarding the age subgroups; the majority of the studied subjects were younger than 48 years old. The ovarian cancer patients were subcategorized into subgroups (Cisplatin sensitive/resistant). Conclusion Comparative analysis between Cisplatin sensitive and resistant ovarian cancer tissues for the Lnc_PVT1, TGF-b and Caspase-3. A high significant difference was observed by Mann- Whitney test (p = 0.001) between Cisplatin sensitive and resistant ovarian cancer patients; Cisplatin resistant tissues showed higher expression levels of the Lnc_PVT1 expression (median 20.0, range: 10 - 92) in Cisplatin sensitive ovarian tissue compared to Cisplatin resistant tissue (median: 83; range: 46-86).

Download Full-text

Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies

International Journal of Molecular Sciences ◽

10.3390/ijms222011220 ◽

2021 ◽

Vol 22 (20) ◽

pp. 11220

Author(s):

Jessica Da Gama Duarte ◽

Luke Thomas Quigley ◽

Anna Rachel Young ◽

Masaru Hayashi ◽

Mariko Miyazawa ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Tumor Antigens ◽

Protein Microarray ◽

Protein Microarrays ◽

Patient Specific ◽

Ovarian Cancers ◽

Therapeutic Uses ◽

Disease Subtypes ◽

New Biomarkers

Ovarian cancers include several disease subtypes and patients often present with advanced metastatic disease and a poor prognosis. New biomarkers for early diagnosis and targeted therapy are, therefore, urgently required. This study uses antibodies produced locally in tumor-draining lymph nodes (ASC probes) of individual ovarian cancer patients to screen two separate protein microarray platforms and identify cognate tumor antigens. The resulting antigen profiles were unique for each individual cancer patient and were used to generate a 50-antigen custom microarray. Serum from a separate cohort of ovarian cancer patients encompassing four disease subtypes was screened on the custom array and we identified 28.8% of all ovarian cancers, with a higher sensitivity for mucinous (50.0%) and serous (40.0%) subtypes. Combining local and circulating antibodies with high-density protein microarrays can identify novel, patient-specific tumor-associated antigens that may have diagnostic, prognostic or therapeutic uses in ovarian cancer.

Download Full-text